[go: up one dir, main page]

MA40345A - Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-lh-indol-3-yl)éthyl]-3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d'alzheimer - Google Patents

Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-lh-indol-3-yl)éthyl]-3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d'alzheimer

Info

Publication number
MA40345A
MA40345A MA040345A MA40345A MA40345A MA 40345 A MA40345 A MA 40345A MA 040345 A MA040345 A MA 040345A MA 40345 A MA40345 A MA 40345A MA 40345 A MA40345 A MA 40345A
Authority
MA
Morocco
Prior art keywords
tetrafluoropropoxy
benzylamine
indol
alzheimer
fluoro
Prior art date
Application number
MA040345A
Other languages
English (en)
Other versions
MA40345B1 (fr
Inventor
Kristine Birklund Andersen
Diego Heidi Lopez De
Michael Harold Rock
Frans Dennis Therkelsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40345(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA40345A publication Critical patent/MA40345A/fr
Publication of MA40345B1 publication Critical patent/MA40345B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA40345A 2014-07-04 2015-07-03 Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-1h-indol-3-yl)éthyl]-3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d'alzheimer MA40345B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04
PCT/EP2015/065176 WO2016001398A1 (fr) 2014-07-04 2015-07-03 Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-lh-indol-3-yl)éthyl] -3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
MA40345A true MA40345A (fr) 2021-04-28
MA40345B1 MA40345B1 (fr) 2021-10-29

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40345A MA40345B1 (fr) 2014-07-04 2015-07-03 Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-1h-indol-3-yl)éthyl]-3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d'alzheimer

Country Status (42)

Country Link
US (1) US10071963B2 (fr)
EP (1) EP3164385B1 (fr)
JP (2) JP6643330B2 (fr)
KR (1) KR102399374B1 (fr)
CN (3) CN112961094A (fr)
AP (1) AP2016009643A0 (fr)
AR (1) AR101109A1 (fr)
AU (1) AU2015282909B2 (fr)
CA (1) CA2951794C (fr)
CL (1) CL2017000002A1 (fr)
CO (1) CO2017000019A2 (fr)
CR (1) CR20160605A (fr)
CY (1) CY1124594T1 (fr)
DK (1) DK3164385T3 (fr)
DO (1) DOP2017000001A (fr)
EA (1) EA035894B1 (fr)
EC (1) ECSP17000222A (fr)
ES (1) ES2893619T3 (fr)
GE (1) GEP20227368B (fr)
HR (1) HRP20211596T8 (fr)
HU (1) HUE056368T2 (fr)
IL (1) IL249428B (fr)
JO (1) JO3639B1 (fr)
LT (1) LT3164385T (fr)
MA (1) MA40345B1 (fr)
MX (1) MX377013B (fr)
MY (1) MY190715A (fr)
NZ (1) NZ727251A (fr)
PE (1) PE20170522A1 (fr)
PH (1) PH12016502477B1 (fr)
PL (1) PL3164385T3 (fr)
PT (1) PT3164385T (fr)
RS (1) RS62380B1 (fr)
RU (1) RU2016151637A (fr)
SG (1) SG11201610334XA (fr)
SI (1) SI3164385T1 (fr)
SM (1) SMT202100575T1 (fr)
SV (1) SV2016005353A (fr)
TN (1) TN2016000549A1 (fr)
TW (1) TWI665188B (fr)
UA (1) UA121547C2 (fr)
WO (1) WO2016001398A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (fr) 2016-12-07 2018-06-13 Sandoz Ag Forme cristalline d'un antagoniste sélectif du récepteur 5-ht6

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
JP2020059724A (ja) 2020-04-16
US10071963B2 (en) 2018-09-11
EA035894B1 (ru) 2020-08-27
PE20170522A1 (es) 2017-05-28
CN112961094A (zh) 2021-06-15
CR20160605A (es) 2017-04-24
AU2015282909A1 (en) 2017-01-05
TN2016000549A1 (en) 2018-04-04
MY190715A (en) 2022-05-12
PH12016502477A1 (en) 2017-04-10
HUE056368T2 (hu) 2022-02-28
JP6643330B2 (ja) 2020-02-12
RU2016151637A (ru) 2018-08-08
AU2015282909B2 (en) 2019-02-07
KR20170023019A (ko) 2017-03-02
IL249428A0 (en) 2017-02-28
KR102399374B1 (ko) 2022-05-17
MA40345B1 (fr) 2021-10-29
JO3639B1 (ar) 2020-08-27
BR112017000127A2 (pt) 2018-01-23
HRP20211596T1 (hr) 2022-01-07
DK3164385T3 (da) 2021-10-11
US20170152227A1 (en) 2017-06-01
JP2017519829A (ja) 2017-07-20
HRP20211596T8 (hr) 2022-03-04
EP3164385B1 (fr) 2021-09-08
EP3164385A1 (fr) 2017-05-10
UA121547C2 (uk) 2020-06-25
WO2016001398A1 (fr) 2016-01-07
AR101109A1 (es) 2016-11-23
DOP2017000001A (es) 2017-03-31
CN106458889A (zh) 2017-02-22
IL249428B (en) 2019-10-31
GEP20227368B (en) 2022-03-25
ES2893619T3 (es) 2022-02-09
CO2017000019A2 (es) 2017-05-31
NZ727251A (en) 2023-06-30
SMT202100575T1 (it) 2021-11-12
CA2951794C (fr) 2023-03-07
SI3164385T1 (sl) 2021-10-29
PL3164385T3 (pl) 2021-12-20
CA2951794A1 (fr) 2016-01-07
CN112961095A (zh) 2021-06-15
AP2016009643A0 (en) 2016-12-31
MX377013B (es) 2025-03-07
SV2016005353A (es) 2017-03-23
TW201625525A (zh) 2016-07-16
CL2017000002A1 (es) 2017-06-23
CY1124594T1 (el) 2022-07-22
TWI665188B (zh) 2019-07-11
RS62380B1 (sr) 2021-10-29
SG11201610334XA (en) 2017-01-27
RU2016151637A3 (fr) 2019-01-28
PH12016502477B1 (en) 2017-04-10
LT3164385T (lt) 2021-10-11
ECSP17000222A (es) 2017-02-24
EA201692485A1 (ru) 2017-05-31
MX2016016895A (es) 2017-04-27
PT3164385T (pt) 2021-10-07

Similar Documents

Publication Publication Date Title
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
EP3796980A4 (fr) Thérapie génique pour la maladie d'alzheimer
EP3633372A4 (fr) Biomarqueur pour la maladie d'alzheimer
EP3626256C0 (fr) Composition pour le traitement des lésions tissulaires
PL3413870T3 (pl) Igmezyna do zastosowania do leczenia choroby alzheimera
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
EP3628008A4 (fr) Compositions et méthodes pour le traitement de la maladie d'alzheimer
MA40345A (fr) Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-lh-indol-3-yl)éthyl]-3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d'alzheimer
EP3706867A4 (fr) Polythérapies pour le traitement de l'ataxie cérébelleuse
EP3310310A4 (fr) Appareil pour le traitement de la maladie de ménière
EP3397267A4 (fr) Peptides pour le traitement d'une maladie à résorption osseuse
ZA202001588B (en) Method of treating alzheimer's disease
FR3031112B1 (fr) Construction d'adn pour le traitement de pathologies oculaires
MA40065A (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
EP3344239A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3664788C0 (fr) Composés pour le traitement de la maladie de von-hippel-lindau